Literature DB >> 8390145

Effects of ORG 2766, a neurotrophic ACTH4-9 analogue, in neuroblastoma cells.

R Murry1, J A McLane, G Gruener.   

Abstract

Treatment of Neuro2a cells with drugs known to affect the integrity of microfilaments and microtubules, as well as with a calcium ionophore produced damage to the cellular membrane that was quantifiable by measuring the release of LDH into the culture medium. Concurrent exposure of the cells to ORG 2766 was found to modulate the release of LDH in a dose- and time-dependent fashion. ORG 2766 treatment was also able to reduce the basal release of LDH into the culture medium. [table: see text] The ORG 2766-induced reduction in LDH release was not due to down-regulation of protein synthesis. The peptide produced significant increases in protein synthesis relative to control conditions at concentrations of 10(-11) to 10(-6) M with 10(-8) M being an optimal dose. SDS-PAGE and 2-D PAGE analysis showed that de novo synthesis of most polypeptides was increased by about 40%. Additionally, a family of polypeptides tentatively identified as actins appear to undergo ORG 2766-dependent post translational charge modifications. These data are consistent with the hypothesis that regulation of transcription and/or translation are mechanisms important to the neurotrophic actions of ORG 2766.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390145     DOI: 10.1111/j.1749-6632.1993.tb18307.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4-9) analogue Org 2766.

Authors:  B Kiburg; C Moorer-van Delft; J J Heimans; P C Huijgens; H H Boer
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

2.  Effects of the ACTH(4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715.

Authors:  B Kiburg; A A van de Loosdrecht; K M Schweitzer; G J Ossenkoppele; L J Müller; J J Heimans; P C Huijgens
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.